Replies to post #130075 on Biotech Values

[acgood]

My first thought was lovenox for TEVA too...but 10 cents per share profit in less than a quarter seems like far too much to have included in guidance

[jq1234]

TEVA said it would be "premature" to submit an NDA at this time for laquinimod and will be working with FDA to design an additional trial for the relapsing-remitting multiple sclerosis (RRMS) product.

http://www.biocentury.com/dailynews/company/2011-11-02/teva-says-laquinimod-nda-submission-premature